We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$3.74B
AUM Growth
-$335M
Cap. Flow
-$614M
Cap. Flow %
-16.42%
Top 10 Hldgs %
21.69%
Holding
674
New
53
Increased
215
Reduced
238
Closed
121

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$107M
2
AAPL icon
Apple
AAPL
+$71.8M
3
TRV icon
Travelers Companies
TRV
+$27.6M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$27.4M
5
AXP icon
American Express
AXP
+$26.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.7%
2 Financials 10.88%
3 Technology 9.76%
4 Communication Services 9.34%
5 Consumer Staples 9.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HIG icon
326
Hartford Financial Services
HIG
$38.5B
$1.48M 0.04%
34,084
-36,085
-51% -$1.65M
RCI icon
327
Rogers Communications
RCI
$17.7B
$1.47M 0.04%
42,649
-7,597
-15% -$285K
CHK
328
DELISTED
Chesapeake Energy Corporation
CHK
$1.46M 0.04%
1,619
-2,308
-59% -$2.87M
EOG icon
329
EOG Resources
EOG
$78B
$1.43M 0.04%
20,180
-200,192
-91% -$16.2M
TE
330
DELISTED
TECO ENERGY INC
TE
$1.43M 0.04%
+53,561
New +$1.43M
ITW icon
331
Illinois Tool Works
ITW
$81.4B
$1.42M 0.04%
15,264
-1,726
-10% -$157K
RSG icon
332
Republic Services
RSG
$66.7B
$1.41M 0.04%
31,958
-27
-0.1% -$1.18K
JCI icon
333
Johnson Controls International
JCI
$87.5B
$1.4M 0.04%
33,775
+3,990
+13% +$180K
TRIL
334
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.37M 0.04%
110,000
S
335
DELISTED
Sprint Corporation
S
$1.37M 0.04%
378,282
-34,862
-8% -$143K
CLDX icon
336
Celldex Therapeutics
CLDX
$2.77B
$1.35M 0.04%
5,733
-3,034
-35% -$661K
EEM icon
337
iShares MSCI Emerging Markets ETF
EEM
$28B
$1.34M 0.04%
41,876
-1,040
-2% -$35.7K
HAL icon
338
Halliburton
HAL
$27.9B
$1.3M 0.03%
38,330
+6,859
+22% +$259K
ODP
339
DELISTED
ODP
ODP
$1.3M 0.03%
23,141
+16,141
+231% +$1.07M
KTWO
340
DELISTED
K2M Group Holdings, Inc
KTWO
$1.3M 0.03%
66,000
+22,000
+50% +$427K
MJN
341
DELISTED
Mead Johnson Nutrition Company
MJN
$1.3M 0.03%
16,463
-60,450
-79% -$4.76M
TCOM icon
342
Trip.com Group
TCOM
$27.5B
$1.3M 0.03%
28,000
+4,000
+17% +$183K
FDX icon
343
FedEx
FDX
$74.5B
$1.29M 0.03%
8,689
+204
+2% +$31.6K
CLVS
344
DELISTED
Clovis Oncology, Inc.
CLVS
$1.27M 0.03%
36,300
-6,500
-15% -$419K
MHFI
345
DELISTED
MCGRAW-HILL FINANCIAL INC COM
MHFI
$1.26M 0.03%
12,811
+1,432
+13% +$136K
MPC icon
346
Marathon Petroleum
MPC
$90.3B
$1.26M 0.03%
24,337
+5,907
+32% +$309K
CBIO
347
Crescent Biopharma
CBIO
$602M
$1.26M 0.03%
2,200
NSC icon
348
Norfolk Southern
NSC
$78.8B
$1.26M 0.03%
14,858
+2,737
+23% +$234K
EXC icon
349
Exelon
EXC
$48.6B
$1.26M 0.03%
63,412
-80,890
-56% -$1.64M
ROP icon
350
Roper Technologies
ROP
$36.3B
$1.26M 0.03%
6,617
+194
+3% +$35.6K

Similar funds

Candriam SCA's Q4 2015 Portfolio in Review

As of Q4 2015, Candriam SCA held 674 positions worth $3.74B, down 8.2% from $4.07B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA withdrew a net $614M in Q4 2015, closing 121 positions and reducing 238 holdings. Its most notable exit was Amgen, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 29% a quarter earlier, followed by Financials and Technology.

Against the trend, Candriam SCA opened a new position in Alphabet (Google) Class A worth $118M.

  • Candriam SCA's largest Q4 2015 buy was Alphabet (Google) Class A: 3,043,280 shares worth $118M.
  • Candriam SCA added most to Intel in Q4 2015, an estimated $61.2M increase.
  • Candriam SCA's biggest Q4 2015 reduction was Colgate-Palmolive, cutting an estimated $21.3M.
  • Candriam SCA fully exited Amgen in Q4 2015, selling an estimated $107M.
  • Candriam SCA's ten largest holdings make up 22% of its $3.74B portfolio in Q4 2015.
  • Candriam SCA opened 53 new positions and closed 121 in Q4 2015.
  • Candriam SCA's portfolio value fell 8.2% quarter-over-quarter to $3.74B.

Based on Candriam SCA's 13F filing for Q4 2015, filed 25 Jan 2016.